US SB3267

Amends Title XVIII of the Social Security Act to add Medicare coverage for blood-based screening tests that detect pre-symptomatic and early-stage Alzheimer's disease and related dementias, effective January 1, 2028

Covered tests must be FDA-cleared, classified, or approved under sections 510(k), 513(f)(2), or 515 of the Federal Food, Drug, and Cosmetic Act

Eligible test types include genomic sequencing blood tests, single-analyte tests, cell-free nucleic acid analysis, multiplex panel tests, whole genome/exome/transcriptome sequencing, protein expression tests, and certain medical imaging based on blood or other biospecimens

Establishes payment provisions under Medicare Part B for these early detection screening tests